Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

Nadine Abdallah; David Murray; Angela Dispenzieri; Prashant Kapoor; Morie A. Gertz; Martha Q. Lacy; Suzanne R. Hayman; Francis K. Buadi; Wilson Gonsalves; Eli Muchtar; Nelson Leung; David Dingli; Taxiarchis Kourelis; Rahma Warsame; Moritz Binder; Robert A. Kyle; S. Vincent Rajkumar; Shaji Kumar

doi:10.1038/s41375-021-01501-0

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

Nadine Abdallah, David Murray, Angela Dispenzieri, Prashant Kapoor, Morie A. Gertz, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, Wilson Gonsalves, Eli Muchtar, Nelson Leung, David Dingli, Taxiarchis Kourelis, Rahma Warsame, Moritz Binder, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar

Hematology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1426-1428
Number of pages	3
Journal	Leukemia
Volume	36
Issue number	5
DOIs	https://doi.org/10.1038/s41375-021-01501-0
State	Published - May 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-021-01501-0

Cite this

Abdallah, N., Murray, D., Dispenzieri, A., Kapoor, P., Gertz, M. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gonsalves, W., Muchtar, E., Leung, N., Dingli, D., Kourelis, T., Warsame, R., Binder, M., Kyle, R. A., Rajkumar, S. V., & Kumar, S. (2022). Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 36(5), 1426-1428. https://doi.org/10.1038/s41375-021-01501-0

Abdallah, N, Murray, D, Dispenzieri, A , Kapoor, P , Gertz, MA , Lacy, MQ, Hayman, SR, Buadi, FK, Gonsalves, W, Muchtar, E, Leung, N, Dingli, D , Kourelis, T, Warsame, R, Binder, M, Kyle, RA, Rajkumar, SV & Kumar, S 2022, 'Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab', Leukemia, vol. 36, no. 5, pp. 1426-1428. https://doi.org/10.1038/s41375-021-01501-0

@article{c9931816b7df452889e7aca39a1e6e7b,

title = "Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab",

author = "Nadine Abdallah and David Murray and Angela Dispenzieri and Prashant Kapoor and Gertz, {Morie A.} and Lacy, {Martha Q.} and Hayman, {Suzanne R.} and Buadi, {Francis K.} and Wilson Gonsalves and Eli Muchtar and Nelson Leung and David Dingli and Taxiarchis Kourelis and Rahma Warsame and Moritz Binder and Kyle, {Robert A.} and Rajkumar, {S. Vincent} and Shaji Kumar",

note = "Funding Information: PK is a principal investigator of research studies for which Mayo Clinic has received funding from AbbVie, Takeda, Sanofi, Janssen, Karyopharm, GlaxoSmithKline, Regeneron Pharmaceuticals, Ichnos Sciences and Amgen. He has served on the Medical advisory board meetings of Sanofi, Pharmacyclics, BeiGene, Cellectar, GSK, X4, and Karyopharm. AD received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. MAG served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. MQL received research funding from Celgene. NL serves on an advisory board for Takeda Pharmaceuticals. SK served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol-Myers Squibb. DM has potential royalties on patents leased to the Binding Site. EM received honorarium from Janssen and consultation fee from Protego (fee paid to institution). The remaining authors declare no competing financial interests.",

year = "2022",

month = may,

doi = "10.1038/s41375-021-01501-0",

language = "English (US)",

volume = "36",

pages = "1426--1428",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Tracking daratumumab clearance using mass spectrometry

T2 - implications on M protein monitoring and reusing daratumumab

AU - Abdallah, Nadine

AU - Murray, David

AU - Dispenzieri, Angela

AU - Kapoor, Prashant

AU - Gertz, Morie A.

AU - Lacy, Martha Q.

AU - Hayman, Suzanne R.

AU - Buadi, Francis K.

AU - Gonsalves, Wilson

AU - Muchtar, Eli

AU - Leung, Nelson

AU - Dingli, David

AU - Kourelis, Taxiarchis

AU - Warsame, Rahma

AU - Binder, Moritz

AU - Kyle, Robert A.

AU - Rajkumar, S. Vincent

AU - Kumar, Shaji

N1 - Funding Information: PK is a principal investigator of research studies for which Mayo Clinic has received funding from AbbVie, Takeda, Sanofi, Janssen, Karyopharm, GlaxoSmithKline, Regeneron Pharmaceuticals, Ichnos Sciences and Amgen. He has served on the Medical advisory board meetings of Sanofi, Pharmacyclics, BeiGene, Cellectar, GSK, X4, and Karyopharm. AD received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. MAG served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. MQL received research funding from Celgene. NL serves on an advisory board for Takeda Pharmaceuticals. SK served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol-Myers Squibb. DM has potential royalties on patents leased to the Binding Site. EM received honorarium from Janssen and consultation fee from Protego (fee paid to institution). The remaining authors declare no competing financial interests.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85123841817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123841817&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01501-0

DO - 10.1038/s41375-021-01501-0

M3 - Article

C2 - 35091659

AN - SCOPUS:85123841817

SN - 0887-6924

VL - 36

SP - 1426

EP - 1428

JO - Leukemia

JF - Leukemia

IS - 5

ER -

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this